Intellipharmaceutics International (I) Stock Price, News & Analysis

Company Overview

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$3.23 to C$3.23
• 52-Week Range: N/A
• Volume: 7,625 shs
• Average Volume: 16,872 shs
• Market Capitalization: C$97.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

I Stock Analysis - Frequently Asked Questions

How do I buy shares of Intellipharmaceutics International?

Shares of I stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Intellipharmaceutics International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intellipharmaceutics International investors own include QuickLogic (QUIK), VBI Vaccines (VBIV), NeuLion (NLN), Micron Technology (MU), Mallinckrodt (MNK), Intellipharmaceutics International (IPCIF) and Fitbit (FIT).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Business Services
• Industry: Wireless Telecommunications
• Sub-Industry: Communication
• Current Symbol: TSE:I
• CUSIP: N/A
• CIK: N/A
• Web: www.intelsat.com
• Phone: +1-416-7983001
• Fax: N/A
• Employees: 1,069
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 30,156,000
• Free Float: N/A
• Market Cap: C$97.40 million
• Optionable: Not Optionable
• Beta: N/A